EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people

Hajira Dambha-Miller iD, William Hinton iD, Christopher R Wilcox iD, Agnieszka Lemanska iD, Mark Joy iD, Michael Feher, Beth Stuart iD, Simon de Lusignan iD, Julia Hippisley-Cox iD, Simon Griffin

Family Practice · 2023

DOI: 10.1093/fampra/cmac094 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Family Practice, 2023. Verfasst von Hajira Dambha-Miller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Primary Care and Population Health, University of Southampton, Southampton, United Kingdom. Hauptthemen laut MEDLINE: COVID-19, Hypertension. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Department of Health, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Concerns have been raised that angiotensin-converting enzyme-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) might facilitate transmission of severe acute respiratory syndrome coronavirus 2 leading to more severe coronavirus disease (COVID-19) disease and an increased risk of mortality. We aimed to investigate the association between ACE-I/ARB treatment and risk of death amongst people with COVID-19 in the first 6 months of the pandemic.

Methods

We identified a cohort of adults diagnosed with either confirmed or probable COVID-19 (from 1 January to 21 June 2020) using computerized medical records from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care database. This comprised 465 general practices in England, United Kingdom with a nationally representative population of 3.7 million people. We constructed mixed-effects logistic regression models to quantify the association between ACE-I/ARBs and all-cause mortality among people with COVID-19, adjusted for sociodemographic factors, comorbidities, concurrent medication, smoking status, practice clustering, and household number.

Results

There were 9,586 COVID-19 cases in the sample and 1,463 (15.3%) died during the study period between 1 January 2020 and 21 June 2020. In adjusted analysis ACE-I and ARBs were not associated with all-cause mortality (adjusted odds ratio [OR] 1.02, 95% confidence interval [CI] 0.85–1.21 and OR 0.84, 95% CI 0.67–1.07, respectively).

Conclusion

Use of ACE-I/ARB, which are commonly used drugs, did not alter the odds of all-cause mortality amongst people diagnosed with COVID-19. Our findings should inform patient and prescriber decisions concerning continued use of these medications during the pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HypertensionAdultHumansAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCohort StudiesAngiotensins

Stichwörter der Autor:innen

COVID-19medicationmortality

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensins

Autor:innen und Institutionen

  • Division of Primary Care and Population Health, University of Southampton, Southampton, United Kingdom.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
  • Department of Clinical and Experimental Medicine, School of Health Sciences, University of Surrey, Surrey, United Kingdom.
  • Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.

ORCID-Profile: Hajira Dambha-Miller, William Hinton, Christopher R Wilcox, Agnieszka Lemanska, Mark Joy, Beth Stuart, Simon de Lusignan, Julia Hippisley-Cox

Förderung

  • Medical Research Council
  • Department of Health
  • Cancer Research UK
  • British Heart Foundation
  • Academic Clinical Lecturer
  • MRC Epidemiology Unit programme
  • NHS
  • Cancer Research UK Oxford Centre

Zitieren

APA

Dambha-Miller, H., Hinton, W., Wilcox, C. R., Lemanska, A., Joy, M., Feher, M., Stuart, B., de Lusignan, S., Hippisley-Cox, J., & Griffin, S. (2023). Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people. Family Practice. https://doi.org/10.1093/fampra/cmac094

Vancouver

Dambha-Miller H, Hinton W, Wilcox CR, Lemanska A, Joy M, Feher M, et al. Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people. Family Practice. 2023. doi:10.1093/fampra/cmac094

BibTeX
@article{DambhaMiller2023,
  author = {Dambha-Miller, Hajira and Hinton, William and Wilcox, Christopher R and Lemanska, Agnieszka and Joy, Mark and Feher, Michael and Stuart, Beth and de Lusignan, Simon and Hippisley-Cox, Julia and Griffin, Simon},
  title = {Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people},
  journal = {Family Practice},
  year = {2023},
  doi = {10.1093/fampra/cmac094}
}
Kostenlos starten →